NCT06024642已完成1 期
Multicenter, Randomized, Double-blind Placebo-controlled, Crossover Study to Investigate Effects of V117957 in Female Subjects With Overactive Bladder Syndrome
Imbrium Therapeutics12 个研究点 分布在 1 个国家目标入组 51 人开始时间: 2022年6月30日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 51
- 试验地点
- 12
- 主要终点
- Change From Baseline in Micturition Episode Components (Micturition, Incontinence, and Urgency) Per 24 Hours.
研究概览
简要总结
The purpose of this study is to evaluate the safety, tolerability and efficacy of V117957 in subjects with overactive bladder syndrome, compared to placebo.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究组 & 干预措施
V117957
Experimental
干预措施: V117957 (Drug)
Placebo
Placebo Comparator
干预措施: Placebo (Drug)
结局指标
主要结局
Change From Baseline in Micturition Episode Components (Micturition, Incontinence, and Urgency) Per 24 Hours.
时间窗: Baseline, Weeks 2, and 8
Subjects were asked to record all micturition episode components into a daily electronic diary during the 3 to 7 days prior to each scheduled clinic visit.
次要结局
未报告次要终点
研究者
研究点 (12)
Loading locations...
相似试验
已完成
1 期
Study of V117957 in Interstitial Cystitis/Bladder Pain SyndromeInterstitial Cystitis/Bladder Pain SyndromeNCT06285214Imbrium Therapeutics47
已完成
2 期
Safety, Tolerability and Efficacy Study of V117957 in Subjects With Insomnia Associated With Alcohol CessationInsomniaNCT04035200Imbrium Therapeutics114
已完成
2 期
VI-1121 for the Treatment Alzheimer's DiseaseAlzheimer's DiseaseNCT01428362VIVUS LLC61
已完成
3 期
Safety and Immunogenicity of V114 in Healthy Adults (V114-019/PNEU-AGE)Pneumococcal InfectionsNCT03950622Merck Sharp & Dohme LLC1,205
已完成
3 期
Safety and Immunogenicity of Catch-up Vaccination Regimens of V114 (V114-024)Pneumococcal InfectionsNCT03885934Merck Sharp & Dohme LLC606